Open Access. Powered by Scholars. Published by Universities.®
ALTERNATIVE OUTCOME MEASURES;; CONTROLLED PHASE II/III;; MYCOPHENOLATE-MOFETIL;; RHEUMATOID-ARTHRITIS;; INTRAVENOUS;; CYCLOPHOSPHAMIDE;; INITIAL VALIDATION;; MURINE LUPUS;; LONG-TERM;; ERYTHEMATOSUS;; TRIAL;; Rheumatology
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Efficacy And Safety Of Abatacept In Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study, R. Furie, K. Nicholls, T. T. Cheng, F. Houssiau, R. Burgos-Vargas, S. L. Chen, J. L. Hillson, S. Meadows-Shropshire, M. Kinaszczuk, J. T. Merrill
Efficacy And Safety Of Abatacept In Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study, R. Furie, K. Nicholls, T. T. Cheng, F. Houssiau, R. Burgos-Vargas, S. L. Chen, J. L. Hillson, S. Meadows-Shropshire, M. Kinaszczuk, J. T. Merrill
Journal Articles
Objective. To compare the efficacy and safety of intravenous (IV) abatacept, a selective T cell costimulation modulator, versus placebo for the treatment of active class III or IV lupus nephritis, when used on a background of mycophenolate mofetil and glucocorticoids. Methods. This was a 12-month, randomized, phase II/III, multicenter, international, double-blind study. A total of 298 patients were treated in 1 of 3 IV treatment arms: placebo, abatacept at the standard weight-tiered dose (approximating 10 mg/kg), or abatacept at 30 mg/kg for 3 months, followed by the standard weight-tiered dose (abatacept 30/10). The primary end point, time to confirmed complete …